Lilly, Boehringer’s empagliflozin succeeds in phase III type 1 diabetes trial

Image: Lilly and Boehringer Ingelheim reported positive results for empagliflozin in EASE program. Photo: courtesy of Guanaco152003/Wikipedia.org.